Nektar

I’ve been waiting to write up the Exubera story for the next edition of Building Biotechnology, and the story just keeps getting better. Exubera is was Pfizer’s innovative answer to the diabetes drug market. The market is so saturated with competitive products, that the only way to capture significant market share is to innovate. Either [...]